Skip to main content
Clinical Trials/NCT04265937
NCT04265937
Recruiting
N/A

Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of High-risk Populations in Chinese Communities

Fudan University1 site in 1 country5,000 target enrollmentJuly 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Fudan University
Enrollment
5000
Locations
1
Primary Endpoint
The frequency of pathogenic or likely pathogenic variants of BRCA1/2 and other genetic susceptibility genes in Chinese community breast cancer population
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is a community-based prospective study and the research object is breast cancer patients. It is planned to take the community as the unit to inform and collect the breast cancer patients who voluntarily participate to carry out the detection of BRCA1, BRCA2, PTEN, CHEK2 and PALB2 genes through the community health service center.

Detailed Description

This is a population-based, prospective, cohort study which has been ongoing in 3 provinces of eastern China since 2019. Up to 5000 breast cancer survivors will conduct BRCA1, BRCA2, PTEN, CHEK2, and PALB2 genetic susceptibility genes testing, fill in clinical and genetic information forms, and collect family history. Mutation rate of BRCA1/2 and other genetic susceptibility genes in Chinese community breast cancer population will be measured. Logistic regression will be performed to establish a prediction model for the probability of BRCA1/2 and other gene mutations. Kin-Cohort method will be used to calculate the penetrance of breast cancer and other common malignancies in BRCA1/2 and other genetic mutation carriers.

Registry
clinicaltrials.gov
Start Date
July 1, 2019
End Date
June 30, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zhen Hu

Professor

Fudan University

Eligibility Criteria

Inclusion Criteria

  • breast cancer patients of any age;
  • both male and female;
  • the subjects signed the informed consent to participate in the study and abide by the study procedure before being selected.

Exclusion Criteria

  • healthy people or other malignant tumor patients without breast cancer;
  • unable to interview the investigator and sign the informed consent due to any reason;
  • it is impossible to collect peripheral blood or oral mucosa samples for any reason.

Outcomes

Primary Outcomes

The frequency of pathogenic or likely pathogenic variants of BRCA1/2 and other genetic susceptibility genes in Chinese community breast cancer population

Time Frame: 1 year

The frequency of pathogenic or likely pathogenic variants and 95% confidence intervals of BRCA1/2 and other genetic susceptibility genes in Chinese community breast cancer population will be measured. After stratifying according to the different clinical characteristics of the patients, chi-square tests will be use to compare the mutation rates of BRCA1/2 gene in different subgroups.

Secondary Outcomes

  • Prediction model of Genetic Susceptibility Gene (BRCA1/2 etc) mutation probability(1 year)
  • Breast cancer penetrance of Genetic Susceptibility Gene (BRCA1/2 etc) carriers(1 year)

Study Sites (1)

Loading locations...

Similar Trials